Drug firms lagging on openness
470908
Six months after the drug industry vowed to make its clinical trials more transparent, and three months after launching a common website to give the public "unprecedented access" to studies both good and bad, drug companies have posted unpublished trial results on the site for just five drugs.
313273
Between the controversy over drug reimportation and activism from a certain state&#39;s attorney general, it has been a nasty year for the pharmaceutical industry.
171088
Only about 10 percent of people who are suitable candidates for two drugs received one of them last year.
512837
Washington --- The Food and Drug Administration, accused in recent weeks of being cozy with the pharmaceutical industry, must open its practices to greater public scrutiny, says a top official of the agency&#39;s besieged Office of New Drugs.
212745
With an ever-larger percentage of prescription drugs and drug ingredients coming to the U.S. market from developing nations such as China and India, Congress is voicing concern that the number of inspections of those plants by the Food and Drug Administration has grown far more slowly.
20326
When a great launch of a good drug is not enough.
175709
Investors care more about the drugmaker's future than its Q4 results.
3117
India and China, countries where the Food and Drug Administration rarely conducts quality-control inspections, have become major suppliers of low-cost drugs and drug ingredients to American consumers. Analysts say their products are becoming pervasive in the generic and over-the-counter marketplace.
569487
Bulging costs keep the drugmaker from showing a profit.
236669
With yet more already-marketed medicines raising the ire of consumer advocates and regulators alike, momentum is building for reform of the governmentâs drug approval and monitoring procedures.
705622
Drug companies are fighting most of the state initiatives, which they say will deny patients access to valuable treatments.
708021
The pharma gives us its quest for bidders.
18004
THE US pharmaceutical industry that exports medicines around the world is facing further scrutiny after a survey revealed nearly one-fifth of its government overseers had experienced pressure to approve drugs about which they had reservations.
226441
Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.
673670
Bristol-Myers Squibb struggles to keep growing amid patent expirations.
589260
Consumer Reports' effort to rate drugs offers a lesson to pharmaceutical companies.
29666
While treatments have multiplied, the operations and processes for delivering those medicines haven't kept pace, slowing health improvement in developing and developed countries. Alexis Madrigal reports from the AAAS annual meeting in Boston.